Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия ela12@yandex.ru
Список исп. литературыСкрыть список 1. Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)». Версия 9 (утв. Минздравом России 26 октября 2020 г.). [Vremennye metodicheskie rekomendatsii "Profilaktika, diagnostika i lechenie novoi koronavirusnoi infektsii (COVID-19)". Versiia 9 (utv. Minzdravom Rossii 26 oktiabria 2020 g.) (in Russian).] 2. Simonnet A, Chetboun M, Poissy J et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity 2020; 28 (7): 1195–9. DOI: 10.1002/oby.22831 3. Leung JM, Niikura M, Tony Yang Ch W, Sin DD. COVID-19 and COPD. Eur Respir J 2020; 56 (2): 2002108. DOI: 10.1183/13993003. 02108-2020 4. An Zyl-Smit RN, Richards G, Leone FT. Tobacco smoking and COVID-19 infection. Lancet Respir Med 2020; 8 (7): 664–5. DOI: 10.1016/S2213-2600(20)30239-3. PMID: 32464099; PMCID: PMC7247798. 5. Lippi G, Sanchis-Gomar F, Henry BM. Active smoking and COVID-19: a double-edged sword. Eur J Intern Med 2020; 77: 123–4. DOI: 10.1016/j.ejim.2020.04.060. PMID: 32439289; PMCID: PMC7252038. 6. Shi Y, Wang G, Cai XP, et al. An overview of COVID-19. J Zhejiang Univ Sci B 2020; 21 (5): 343–60. DOI: 10.1631/jzus.B2000083. PMID: 32425000; PMCID: PMC7205601. 7. Feng Y, Ling Y, Bai T et al. COVID-19 with different severity: a multi-center study of clinical features. Am J Respir Crit Care Med 2020; 201: 1380–8. DOI: 10.1164/rccm.202002-0445OC 8. Cai Q, Chen F, Wang T et al. Obesity and COVID-19 severity in a designated hospital in Shenzhen, China. Diabetes Care 2020; 43: 1392–8. 9. Leung JM, Yang CX, Tam A et al. ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19. Eur Respir J 2020; 55 (5): 2000688. DOI: 10.1183/ 13993003.00688-2020 10. Zhang H, Rostami MR, Leopold PL et al. Expression of the SARS-CoV-2 ACE2 receptor in the human airway epithelium. Am J Respir Crit Care Med 2020; 202: 219–29. 11. Ahmed H, Sayed A, Munir M et al. A Clinical Review of COVID-19; Pathogenesis, Diagnosis, and Management. Curr Pharm Des 2020. E-pub Ahead of Print. DOI: 10.2174/1381612826666201222162509 12. Ojo AS, Balogun SA, Williams OT, Ojo OS. Pulmonary Fibrosis in COVID-19 Survivors: Predictive Factors and Risk Reduction Strategies. Pulm Med 2020: 6175964. E-pub Ahead of Print. DOI: 10.1155/2020/6175964. PMID: 32850151; PMCID: PMC7439160. 13. Lagi F, Piccica M, Graziani L et al. Early experience of an infectious and tropical diseases unit during the coronavirus disease (COVID-19) pandemic, Florence, Italy, February to March 2020. Euro Surveill 2020; 25: 2000556. DOI: 10.2807/1560-7917.ES.2020.25.17.2000556 14. Tyurina YY, Mikulska-Ruminska K et al. Pseudomonas aeruginosa utilizes host polyunsaturated phosphatidylethanolamines to trigger theft-ferroptosis in bronchial epithelium. J Clin Invest 2018; 128 (10): 4639–53. DOI: 10.1172/JCI99490 15. Kolb M, Vašáková M. The natural history of progressive fibrosing interstitial lung diseases. Respir Res 2019; 20 (1): 57. DOI: 10.1186/s12931-019-1022-1 16. Raghu G, Remy-Jardin M, Myers JL et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 2018; 198: e44–e68. DOI: 10.1164/rccm.201807-1255ST 17. Sheng G, Chen P, Wei Y et al. Viral Infection Increases the Risk of Idiopathic Pulmonary Fibrosis: A Meta-Analysis. Chest 2020; 157 (5): 1175–87. DOI: 10.1016/j.chest.2019.10.032 18. Anand Devaraj. Imaging: how to recognise idiopathic pulmonary fibrosis. European Respiratory Review 2014; 23: 215–9; DOI: 10.1183/09059180.00001514 19. Rai DK, Sharma P, Kumar R. Post Covid-19 pulmonary fibrosis- Is it reversible? Indian J Tuberc 2020; 10. E-pub Ahead of Print. DOI: 10.1016/j.ijtb.2020.11.003 20. Громова O.A., Торшин И.Ю. Сочетанная терапия для лечения ОРВИ: анализ комбинированного комплекса АнвиМакс. Медицинский алфавит. 2020; 21: 33–48. [Gromova O.A., Torshin I.Yu. Combined therapy for treatment of acute respiratory viral infections: analysis of combined complex AnviMax. Medical alphabet. 2020; 21: 33–48. DOI: 10.33667/2078-5631-2020-21-33-48 (in Russian).] 21. Кузин В.Б., Ловцова Л.В., Барсук А.Л. Исследование клинической эффективности и переносимости препарата Антигриппин-Максимум при лечении ОРВИ (гриппа). Справочник поликлинического врача. 2010; 1: 3–7. [Kuzin V.B., Lovtsova L.V., Barsuk A.L. Issledovanie klinicheskoi effektivnosti i perenosimosti preparata Antigrippin-Maksimum pri lechenii ORVI (grippa). Spravochnik poliklinicheskogo vracha. 2010; 1: 3–7 (in Russian).] 22. Hemila H, Chalker E. Vitamin C for preventing and treating the common cold. Cochrane Database SystRev 2013; 1: CD 000980. 23. Bai L, Li A, Gong C et al. Protective effect of rutin against bleomycin induced lung fibrosis: Involvement of TGF-beta1/alpha-SMA/Col I and III pathway. Biofactors 2020. DOI: 10,1002/biof.1629. PubMed ID: 32233122. 24. Ortolani O, Conti A, De Gaudio AR et al. Protective effects of N-acetylcysteine and rutin on the lipid peroxidation of the lung epithelium during the adult respiratory distress syndrome. Shock 2000; 13 (1): 14–8. DOI: 10.1097/00024382-200013010-00003. PMID: 10638663. 25. Ragheb SR et al. Impact of Rutin and Vitamin C combination on oxidative stress and glycemic control in patients with type 2 diabetes. Clinical Nutrition ESPEN 2020; 35: 128–35. DOI: 10.1016/j.clnesp.2019.10.015